AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 62 min read$KMTS

Ford Alfred J Jr sold $151K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 6,275 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.09 ($0.15M total) on 2026-08-04.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 6, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CCO: 6,275 shares at $24.0862 on 2026-08-04, totaling $151,140.90, with post-sale holdings of 99,564 shares and no disclosed pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to change valuation without corroborating company news.

03

What to watch

The filing does not state motivations, remaining option/RSU activity, or whether other insiders are buying/selling around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 after-hours; sale dated 2026-08-04

Background

The article is a primary-source SEC Form 4 insider transaction for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Form 4 shows CCO Alfred J. Ford Jr sold 6,275 shares of KMTS for about $151.1K on 2026-08-04.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental signal from the filing alone.

Evidence & confidence

The disclosure is a Form 4 insider transaction, not earnings, guidance, or a corporate event. The article provides sale size and price but no accompanying company-specific news.

Market effects

Sector

Minimal. Insider sales in a single small-cap medical technology name typically do not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification, taxes, or planned liquidity needs; without a 10b5-1 plan, it still does not imply negative company fundamentals.

Key entities

  • issuer
    KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Ford Alfred J Jr

    Chief Commercial Officer who sold shares via an open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min
SEP 14
$KMTSHigh

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported

SEC EDGAR 8-K2 min